A prodrug approach toward the development of water soluble fluoroquinolones and structure-activity relationships of quinoline-3-carboxylic acids

Journal of Medicinal Chemistry

Volumn 47, Issue 19, 2004, Pages 4693-4709

  Baker, William R ^a   Cai, Shaopei ^a   Dimitroff, Martin ^a   Fang, Liming ^a   Huh, Kay K ^a   Ryckman, David R ^a   Shang, Xiao ^a   Shawar, Ribhi M ^a   Therrien, Joseph H ^a  

^a Chiron Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 QUINOLINECARBOXYLIC ACID DERIVATIVE; ALKALINE PHOSPHATASE; CARBOXYLIC ACID DERIVATIVE; CIPROFLOXACIN; CYCLOPROPANE; NALIDIXIC ACID; OFLOXACIN; PA 2789; PA 2808; PRODRUG; PYRROLIDINE DERIVATIVE; QUINOLONE DERIVATIVE; TOBRAMYCIN; TOSUFLOXACIN; UNCLASSIFIED DRUG;

AEROSOL; AGAR GEL DIFFUSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; IN VIVO STUDY; LUNG INFECTION; MALE; MOUSE; NONHUMAN; PH; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CARBOXYLIC ACIDS; FLUOROQUINOLONES; LUNG; MOLECULAR STRUCTURE; NALIDIXIC ACID; PHOSPHORIC ACID ESTERS; PIPERAZINES; PRODRUGS; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 4444282620     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0497895     Document Type: Article

References (29)

1. Read, R. C.; Morrissey, I.; Ambler, J. E. Respiratory Tract Infections and Fluoroquinolones; Science Press: London, 2002; pp 1-5.
2. (a) Domagala, J. M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 1994, 33, 685-706.
3. (b) Peterson, L. R. Quinolone molecular structure-activity relationships: What have we learned about improving antimicrobial activity. Clin. Infect. Dis. 2001, 33, S180-S186.
4. (c) Applebaum, P. C.; Hunter, P. A. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob. Agents 2000, 16, 5-15.
5. (d) Pickerill, K. E.; Paladino, J. A.; Schentag, J. J. Comparison of the fluoroquinolones based on pharmacokenetic and pharmacodynamic parameters. Pharmacotherapy 2000, 20, 417-428.
6. (e) Turnridge, J. Pharmacokenetics and pharmacodynamics of fluoroquinolones. Drugs 1999, 58, 29-36.
7. (f) Eliopoulos, G. M. Activity of newer fluoroquinolones in vitro against Gram-positive bacteria. Drugs 1999, 58, 23-28.
8. (g) Bosso, J. A. An overview of the new fluoroquinolone antibiotics. J. Infect. Dis. Pharmacother. 1998, 3, 1-8.
9. (h) Blondeau, J. M. Expanded activity and utility of the new fluoroquinolones: a review. Clin. Ther. 1999, 21, 3-40.
10. (i) Ball, P.; Fernald, A.; Tillotson, G. Therapeutic advances of new fluoroquinolones. Exp. Opin. Invest. Drugs 1998, 7, 761-783.
11. (j) Grossman, R. F. The role of fluoroquinolones in respiratory tract infections. J. Antimicrob. Chemother. 1997, 40, 59-62.
12. (k) Chu, D. T. W.; Fernandes, P. B. Structure-activity relationships of the fluoroquinolones. Antimicrob. Agents Chemother. 1989, 33, 131-135.
13. (a) Hooper, D. C. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 2001, 32, S9-S15.
14. (b) Drlica, K. Mechanism of fluoroquinolone action. Curr. Opin. Microbiol. 1999, 2, 504-508.
15. Chu, D. T. W.; Fernandes, P. B.; Claiborne, A. K.; Pihuleac, E.; Nordeen, C. W.; Maleczka, R. E., Jr.; Pernet, A. G. Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents. J. Med. Chem. 1985, 28, 1558-1564.
16. (a) Capelli, A.; Cerutti, C. G.; Lusuardi, M.; Donner, C. F. Identification of human pulmonary alkaline phosphatase isoenzymes. Am. J. Respir. Crit. Care Med. 1997, 155, 1448-1452.
17. (b) Capelli, A.; Lusuardi, M.; Cerutti, C. G.; Donner, C. F. Lung alkaline phosphatase as a marker of fibrosis in chronic interstitial discorders. Am. J. Respir. Crit. Care Med. 1997, 155, 249-253.
18. Jung, M. E.; Yang, E. C.; Vu, B. T.; Kiankarimi, M.; Spyrou, E.; Kaunitz, J. Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials. J. Med. Chem. 1999, 42, 3899-3909.
19. Chu, D. T. W.; Fernandes, P. B. Recent developments in the field of quinolone antibacterial agents. Adv. Drug Res. 1991, 21, 39-144.
20. Clay, R. J.; Collom, T. A.; Karrick, G. L.; Wemple, J. A safe, economical method for the preparation of β-oxo esters. Synthesis 1993, 290-292.
21. (a) Guzaev, Andrei P.; Manoharan, Muthiah A novel protecting strategy for internucleoside phosphate and phosphorothiate groups. Nucleosides, Nucleotides Nucleic Acids 2001, 20, 1011-1014.
22. (b) Beauve, C.; Bouchet, M.; Touillaux, R.; Fastrez, J. Marchand-Brynaert, J. Synthesis, reactivity and biochemical evaluation of 1,3-substituted azetidin-2-ones as enzyme inhibitors. Tetrahedron 1999, 55, 13301-13320.
23. (a) Man, I.; Traynor, N. J.; Ferguson, J. Recent developments in fluoroquinolone phototoxicity. Photodermatol, Photoimmunol. Photomed. 1999, 15, 32-33.
24. (b) Ball, P.; Mandell, L.; Yoshihito, N.; Tillotson, G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999, 21, 407-421.
25. (c) Suto, M. J.; Domagala, J. M.; Rolang, G. E.; Mailloux, G. B.; Cohen, M. A. Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity and antimicrobial activity. J. Med. Chem. 1992, 35, 4745-4750.
26. Sanchez, J. P.; Gogliotti, R. D.; Domagala, J. M.; Gracheck, S. J.; Huband, M. D.; Sesnie, J. A.; Cohen, M. A.; Shapiro, M. A. The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. J. Med. Chem. 1995, 38, 4478-4487.
27. Sanchez, J. P.; Domagala, J. M.; Hagen, S. E.; Heifetz, C. L.; Hutt, M. P.; Nichols, J. B.; Trehan, A. K. Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinolone-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids. J. Med. Chem. 1988, 31, 989-991.
28. Bouzard, D.; Di Cesare, P.; Essiz, M.; Jacquet, J. P.; Ledoussal, B.; Remuzon, P. Kessler, R. E.; Fung-Tomc, J. Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acids. J. Med. Chem. 1992, 35, 518-525.
29. Godden, D. J.; Borland, C.; Lowry, R.; Higenbottam, T. W. Chemical specificity of coughing in man. Clin. Sci. 1986, 70, 301-306.